Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866538 · ClinicalTrials.gov registry record · Phase 4
Budesonide in Patients With Immune Mediated Enteropathies
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03866538: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT03866538 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866538, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Researchers are trying to determine if withdrawal of budesonide therapy in patients with immune-mediated enteropathies doing well on therapy will result in worsening symptoms, histology, quality of life, and micronutrient/nutritional status when compared to continued therapy.
Interventions
- DRUG Withdrawal of Oral Budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-09-10 |
| Est. Completion | 2021-10-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866538
The ClinicalTrials.gov registry entry for NCT03866538 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Withdrawal of Oral Budesonide is the first listed.
NCT03866538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866538 about?
NCT03866538 is a clinical study titled "Budesonide in Patients With Immune Mediated Enteropathies". Researchers are trying to determine if withdrawal of budesonide therapy in patients with immune-mediated enteropathies doing well on therapy will result in worsening symptoms, histology, quality of life, and micronutrient/nutritional status when compared to continued therapy.
What is the current status of trial NCT03866538?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2019-09-10. Estimated completion is 2021-10-19.
What interventions are being tested in trial NCT03866538?
The interventions under investigation include: Withdrawal of Oral Budesonide (DRUG).
Who is sponsoring clinical trial NCT03866538?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.